BR112018007664A2 - antagonistas de ep4 - Google Patents

antagonistas de ep4

Info

Publication number
BR112018007664A2
BR112018007664A2 BR112018007664A BR112018007664A BR112018007664A2 BR 112018007664 A2 BR112018007664 A2 BR 112018007664A2 BR 112018007664 A BR112018007664 A BR 112018007664A BR 112018007664 A BR112018007664 A BR 112018007664A BR 112018007664 A2 BR112018007664 A2 BR 112018007664A2
Authority
BR
Brazil
Prior art keywords
formulations
antagonists
formula
methods
pharmaceutically acceptable
Prior art date
Application number
BR112018007664A
Other languages
English (en)
Other versions
BR112018007664B1 (pt
Inventor
Custar Daniel
Fang Frank
Du Hong
Choi Hyeong-Wook
Lee Jaemoon
Li Jing
Postema Maarten
Yu Robert
Zheng Wanjun
Zhu Xiaojie
Jiang Yimin
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BR112018007664A2 publication Critical patent/BR112018007664A2/pt
Publication of BR112018007664B1 publication Critical patent/BR112018007664B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

fornecemos compostos dados pela fórmula i, que é mostrado na fig. 3, ou sais farmaceuticamente aceitáveis destes, assim como formulações destes e métodos de uso daqueles compostos e formulações para o tratamento de câncer.
BR112018007664-3A 2015-10-16 2016-10-14 Compostos antagonistas de ep4, composição compreendendo o composto e uso dos mesmos para tratar câncer BR112018007664B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562242748P 2015-10-16 2015-10-16
US201562242734P 2015-10-16 2015-10-16
US62/242,734 2015-10-16
US62/242,748 2015-10-16
BD252/2016 2016-10-13
BD2522016 2016-10-13
PCT/US2016/057135 WO2017066633A1 (en) 2015-10-16 2016-10-14 Ep4 antagonists

Publications (2)

Publication Number Publication Date
BR112018007664A2 true BR112018007664A2 (pt) 2018-11-06
BR112018007664B1 BR112018007664B1 (pt) 2023-12-19

Family

ID=58518017

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018007664-3A BR112018007664B1 (pt) 2015-10-16 2016-10-14 Compostos antagonistas de ep4, composição compreendendo o composto e uso dos mesmos para tratar câncer

Country Status (10)

Country Link
US (3) US10316040B2 (pt)
EP (1) EP3362454B1 (pt)
JP (2) JP6860559B2 (pt)
CN (1) CN108473497B (pt)
AU (1) AU2016338679B2 (pt)
BR (1) BR112018007664B1 (pt)
CA (1) CA3002144C (pt)
IL (1) IL258737A (pt)
MX (1) MX2018004664A (pt)
WO (1) WO2017066633A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
HUE056080T2 (hu) 2017-05-18 2022-01-28 Idorsia Pharmaceuticals Ltd Fenilszármazékok mint PGE2 receptor modulátorok
TW201900178A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 作為pge2受體調節劑之嘧啶衍生物
SI3625224T1 (sl) 2017-05-18 2021-11-30 Idorsia Pharmaceuticals Ltd N-substituirani indolni derivati
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
ES2896476T3 (es) 2017-05-18 2022-02-24 Idorsia Pharmaceuticals Ltd Derivados de pirimidina
KR20200118037A (ko) * 2018-02-05 2020-10-14 셴젠 이오노바 라이프 사이언스 시오., 엘티디. 암 또는 염증성 질환들을 치료하기 위한 헤테로비시클릭 카르복시산들
EP3759114A4 (en) * 2018-03-02 2021-12-15 Shenzhen Ionova Life Science Co., Ltd. HETEROBICYCLIC CARBOXYLIC ACIDS AND THEIR SALTS
US20220064113A1 (en) 2019-01-22 2022-03-03 Keythera (Suzhou) Pharmaceuticals Co. Ltd. Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
TW202228674A (zh) 2020-11-13 2022-08-01 日商小野藥品工業股份有限公司 藉由併用ｅｐ４拮抗藥與免疫檢查點抑制物質而進行之癌症治療

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE294943C (pt)
GB8426447D0 (en) 1984-10-19 1984-11-28 Kodak Ltd Photographic colour couplers
JPS6296940A (ja) 1985-10-24 1987-05-06 Fuji Photo Film Co Ltd 熱現像感光材料
US5126340A (en) 1986-10-16 1992-06-30 American Cyanamid Company 4-[(substituted)alkylcarbonyl]-4,5-dihydro and -4,5,6,7-tetrahydro-7-[(substituted)-phenyl]pyrazolo[1,5-a]pyrimidine-3-carbonitriles
US4847256A (en) 1986-10-16 1989-07-11 American Cyanamid Company 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines
US4963553A (en) 1986-10-16 1990-10-16 American Cyanamid Co. 4-[(substituted) alkylcarbonyl]-4,5-dihydro- and -4,5,6,7-tetrahydro-7-[(substituted)phenyl]pyrazolo[1,5-a]pyrimidines
US5215982A (en) 1989-11-10 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
DD294943A5 (de) 1990-06-05 1991-10-17 Wilhelm-Pieck-Uni. Rostock Direktorat Fuer Forschung,De Verfahren zur herstellung von kondensierten n-heterocyclen
JP2631160B2 (ja) 1990-11-06 1997-07-16 富士写真フイルム株式会社 シアンカプラー、シアン画像形成方法及びハロゲン化銀カラー写真感光材料
JPH04190348A (ja) 1990-11-26 1992-07-08 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
US5210200A (en) 1990-11-29 1993-05-11 Fuji Photo Film Co., Ltd. Heterocyclic dye compounds
US5880066A (en) 1990-12-11 1999-03-09 Monsanto Company Safened herbicidal sulfonamide compositions
US5484760A (en) 1990-12-31 1996-01-16 Monsanto Company Herbicide antidotes as safeners for reducing phytotoxicity resulting from synergistic interaction between herbicides and other pesticides
TW274551B (pt) 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
TW284688B (pt) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
JP2893100B2 (ja) 1991-11-27 1999-05-17 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料
JP2772884B2 (ja) 1992-01-28 1998-07-09 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料
JPH05341430A (ja) 1992-06-12 1993-12-24 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US5405969A (en) 1993-12-10 1995-04-11 Eastman Kodak Company Manufacture of thioether compounds
US6472416B1 (en) 1999-08-27 2002-10-29 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors
JP4233238B2 (ja) 2000-07-06 2009-03-04 富士フイルム株式会社 インク用着色微粒子分散物、それを用いたインクジェット記録用インクおよびインクジェット記録方法
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
KR20030082982A (ko) 2001-03-14 2003-10-23 그뤼넨탈 게엠베하 치환된 피라졸로피리미딘 및 티아졸로피리미딘
US6783558B2 (en) 2001-03-15 2004-08-31 Kao Corporation Hair coloring method and composition
JPWO2003004497A1 (ja) 2001-07-05 2004-10-28 住友製薬株式会社 新規複素環化合物
JP2003222985A (ja) 2001-11-22 2003-08-08 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料の感度を増加させる方法
JP2003327860A (ja) 2002-05-09 2003-11-19 Konica Minolta Holdings Inc 着色組成物、着色微粒子分散物、インクジェット用インク、インクジェット記録方法
EP1572113B1 (en) 2002-08-26 2017-05-17 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
JP2004091369A (ja) 2002-08-30 2004-03-25 Sumitomo Pharmaceut Co Ltd 新規ビフェニル化合物
AU2003274022A1 (en) 2002-10-17 2004-05-04 Syngenta Participations Ag 3-heterocyclylpyridine derivatives useful as herbicides
WO2004035564A1 (en) 2002-10-17 2004-04-29 Syngenta Participations Ag Pyridine derivatives useful as herbicides
JP4608869B2 (ja) 2002-12-12 2011-01-12 コニカミノルタホールディングス株式会社 光電変換材料用半導体、光電変換素子及び太陽電池
JP2004277337A (ja) 2003-03-14 2004-10-07 Sumitomo Pharmaceut Co Ltd ピラゾロ［１，５−ａ］ピリミジン誘導体
JP4419421B2 (ja) 2003-04-15 2010-02-24 コニカミノルタホールディングス株式会社 光電変換材料用半導体、光電変換素子及び太陽電池
JP4419424B2 (ja) 2003-04-17 2010-02-24 コニカミノルタホールディングス株式会社 光電変換材料用半導体、光電変換素子及び太陽電池
JP2004355960A (ja) 2003-05-29 2004-12-16 Konica Minolta Holdings Inc 光電変換材料用半導体、光電変換素子及び太陽電池
JP2005035932A (ja) 2003-07-15 2005-02-10 Fuji Photo Film Co Ltd ４−置換ピラゾロ［１，５−ａ］ピリミジンジオン誘導体の製造方法
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
JP2005239611A (ja) 2004-02-25 2005-09-08 Takeda Chem Ind Ltd ピラゾロピリミジン誘導体およびその用途
US7288123B2 (en) 2004-08-26 2007-10-30 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
CN101010061A (zh) 2004-08-26 2007-08-01 宝洁公司 角蛋白染色化合物、包含该化合物的角蛋白染色组合物以及它们的应用
AU2005296305A1 (en) 2004-10-12 2006-04-27 Decode Genetics Ehf Sulfonamide peri-substituted bicyclics for occlusive artery disease
RU2007115522A (ru) 2004-10-12 2008-10-27 Декод Дженетикс Ехф (Is) Пери-замещенные бициклические карбоновые кислоты для лечения окклюзионного заболевания артерий
JP2006248195A (ja) 2005-03-14 2006-09-21 Fuji Photo Film Co Ltd 感熱記録材料
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
CA2645018A1 (en) 2006-03-08 2007-09-13 Takeda Pharmaceutical Company Limited Pharmaceutical combination
JP5244091B2 (ja) * 2006-04-24 2013-07-24 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのインドールアミド誘導体
WO2008019309A1 (en) 2006-08-04 2008-02-14 Metabasis Therapeutics, Inc. Novel inhibitors of fructose 1,6-bisphosphatase
CN101622230B (zh) 2007-02-26 2012-08-22 默克弗罗斯特加拿大有限公司 作为ep4受体拮抗剂的吲哚和二氢吲哚环丙基酰胺衍生物
US8063249B1 (en) 2008-04-25 2011-11-22 Olema Pharmaceuticals, Inc. Substituted triphenyl butenes
JP2009282350A (ja) 2008-05-23 2009-12-03 Konica Minolta Business Technologies Inc 静電荷像現像用トナー
JP5151684B2 (ja) 2008-05-23 2013-02-27 コニカミノルタビジネステクノロジーズ株式会社 トナーの製造方法およびトナー
JP2010026048A (ja) 2008-07-16 2010-02-04 Konica Minolta Business Technologies Inc カラートナー
JP5536773B2 (ja) * 2008-08-14 2014-07-02 ベータ・ファーマ・カナダ・インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのヘテロ環式アミド誘導体
US20110230472A1 (en) 2008-08-29 2011-09-22 Shionogi & Co., Ltd. Ring-fused azole derivative having pi3k-inhibiting activity
US8853125B2 (en) 2008-09-24 2014-10-07 Basf Se Pyrazole compounds for controlling invertebrate pests
WO2010048559A2 (en) 2008-10-24 2010-04-29 Calcimedica Inc. Phenylpyrazole inhibitors of store operated calcium release
WO2010096115A1 (en) 2008-10-29 2010-08-26 Apath, Llc Compounds, compositions and methods for control of hepatitis c viral infections
US9776963B2 (en) 2008-11-10 2017-10-03 The Trustees Of The University Of Pennsylvania Small molecule CD4 mimetics and uses thereof
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
US20120295845A1 (en) 2009-11-23 2012-11-22 Pfizer Inc Imidazo-pyrazoles as gpr119 inhibitors
CN102770159A (zh) 2010-02-22 2012-11-07 拉夸里亚创药株式会社 Ep-4受体拮抗剂在治疗il-23介导疾病中的用途
CN102770435B (zh) 2010-02-26 2015-11-25 田边三菱制药株式会社 吡唑并嘧啶类化合物及其作为pde10抑制剂的用途
WO2011156632A2 (en) 2010-06-09 2011-12-15 Georgetown University Compositions and methods of treatment for tumors in the nervous system
PE20140011A1 (es) 2010-09-03 2014-01-31 Forma Tm Llc Compuestos y composiciones novedosos para la inhibicion de nampt
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
RS55566B1 (sr) 2010-09-21 2017-05-31 Eisai R&D Man Co Ltd Farmaceutska kompozicija
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
EP2680852A1 (en) 2011-03-02 2014-01-08 Lead Discovery Center GmbH Pharmaceutically active disubstituted triazine derivatives
EA201391558A1 (ru) 2011-04-20 2014-05-30 Глэксо Груп Лимитед Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения
CN103702980B (zh) 2011-07-04 2016-10-05 罗达制药生物技术有限责任公司 环胺衍生物作为ep4受体拮抗剂
WO2013036994A1 (en) 2011-09-16 2013-03-21 Biota Scientific Management Pty Ltd Compounds for the treatment of hcv
US9169205B2 (en) 2012-10-08 2015-10-27 Boehringer Ingelheim International Gmbh Pyrrolidine derivatives, pharmaceutical compositions and uses thereof
CN102977106B (zh) 2012-12-12 2014-12-10 中国药科大学 一类具有外周镇痛作用的κ阿片受体激动剂
HUE031980T2 (en) 2013-04-25 2017-08-28 Beigene Ltd Condensed heterocyclic compounds as protein kinase inhibitors
JP6409055B2 (ja) 2013-05-20 2018-10-17 ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーションＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｗａｓｈｉｎｇｔｏｎ Ｔｈｒｏｕｇｈ Ｉｔｓ Ｃｅｎｔｅｒ Ｆｏｒ Ｃｏｍｍｅｒｃｉａｌｉｚａｔｉｏｎ Ｃｄｐｋ１の５−アミノピラゾール−４−カルボキサミド阻害剤
JP5954278B2 (ja) 2013-08-09 2016-07-20 コニカミノルタ株式会社 静電荷像現像用トナー、その製造方法および画像形成方法
FR3014687B1 (fr) 2013-12-13 2016-11-25 Oreal Procede de coloration des matieres keratiniques a partir d'oligomeres et/ou de polymeres colores issus de coupleurs, composition et agent de coloration
KR102535283B1 (ko) 2014-05-23 2023-05-22 에자이 알앤드디 매니지먼트 가부시키가이샤 암의 치료를 위한 조합 요법
WO2016088903A1 (en) 2014-12-05 2016-06-09 Takeda Pharmaceutical Company Limited Heterocyclic compounds

Also Published As

Publication number Publication date
US10316040B2 (en) 2019-06-11
BR112018007664B1 (pt) 2023-12-19
US20190315754A1 (en) 2019-10-17
WO2017066633A1 (en) 2017-04-20
MX2018004664A (es) 2018-08-24
AU2016338679A1 (en) 2018-06-07
JP7090770B2 (ja) 2022-06-24
CN108473497A (zh) 2018-08-31
US10941148B2 (en) 2021-03-09
US11434246B2 (en) 2022-09-06
CA3002144C (en) 2024-01-23
CN108473497B (zh) 2021-09-10
US20180305362A1 (en) 2018-10-25
US20210347779A1 (en) 2021-11-11
EP3362454B1 (en) 2021-12-08
CA3002144A1 (en) 2017-04-20
EP3362454A1 (en) 2018-08-22
AU2016338679B2 (en) 2021-05-06
KR20180083863A (ko) 2018-07-23
JP6860559B2 (ja) 2021-04-14
JP2018530595A (ja) 2018-10-18
JP2021100969A (ja) 2021-07-08
IL258737A (en) 2018-06-28

Similar Documents

Publication Publication Date Title
BR112018007664A2 (pt) antagonistas de ep4
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
BR112015024530A8 (pt) compostos derivados de naftiridina úteis como antagonistas de integrina alfa-v-beta-6, composição farmacêutica, e, uso de um composto
BR112015029989A2 (pt) Uso de dianidrogalactitol e análogos e derivados do mesmo para tratar glioma maligno recorrente ou tumor cerebral secundário progressivo
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112017004589A2 (pt) composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
BR112015029495A2 (pt) compostos heterocíclicos como inibidores da via de sinalização hedgehog
BR112017000520A2 (pt) composto ou sal do mesmo, uso um composto ou de um sal, e, kit.
CY1120142T1 (el) Ενωσεις αζετιδινυλοξυφαινυλοπυρρολiδινης
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/10/2016, OBSERVADAS AS CONDICOES LEGAIS